| Similar Articles |
|---|
 |
The Motley Fool
October 31, 2007
Brian Orelli |
A Slimmer Sepracor The big-pharma company reduces its sales team after a government decision forces price cuts for one of its top drugs. Investors, take note.   |
The Motley Fool
July 30, 2007
Brian Orelli |
Why Sepracor Investors Can't Sleep Shares of the drug maker were hammered after the company announced lower than expected earnings and a not so bright future. |
The Motley Fool
September 12, 2007
Brian Orelli |
Butterflies Move Eastward Sepracor and GlaxoSmithKline ink a deal to market Lunesta worldwide. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia sufferers are on medication, so there's certainly room for the market to grow. |
The Motley Fool
October 27, 2006
Brian Lawler |
Wake Up to Sepracor Its insomnia drug is taking hold, and sales of its other drug jumped, too. If Sepracor can slim down its marketing spending, earnings should skyrocket. Investors, take note. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Snoozing for Sepracor The pharmaceutical sees troubling sales trends with a key product. Investors, take note. |
The Motley Fool
July 21, 2006
Brian Lawler |
Sepracor Stays Alert Insomnia drug Lunesta's sales growth is anything but sleepy. Despite the shares' ups and downs, Sepracor's most recent earnings suggest that its performance remains admirably steady. |
The Motley Fool
December 17, 2004
Brian Gorman |
Sepracor's Dream Drug? Investors should be awake to Lunesta's potential pitfalls. |
The Motley Fool
May 2, 2008
Brian Orelli |
Sepracor Diversifies to Sleep Better With its two top drugs in decline, diversification was the only answer for Sepracor. |
BusinessWeek
January 17, 2005
Weintraub & Barrett |
Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news. |
The Motley Fool
October 30, 2007
Brian Orelli |
Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note. |
The Motley Fool
October 26, 2004
Charly Travers |
Sepracor's Tough Road to Profits Will insomnia drug Estorra take the company to the promised land? |
The Motley Fool
February 17, 2005
Karl Thiel |
Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market. |
The Motley Fool
December 11, 2007
Brian Orelli |
Medicare Whacks Oncology Drugs Bad news for some pharmaceutical companies as Medicare announces it is reducing the reimbursement rate for two lymphoma drugs. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
BusinessWeek
May 31, 2004
Gene G. Marcial |
Seeking Sepracor? Sepracor is takeover bait because it is just what Big Pharma wants: diversified drugs and the newly approved sleep-disorder medication with blockbuster potential, Estorra. |
ifeminists
September 14, 2005
Tony Zizza |
Lunesta Lunacy Big Pharma will not stop telling us that we need countless prescription medicines to treat all that troubles us unless we actually take the time to listen to what we're being told. To believe that as adults we need Lunesta to cope with electric bills is lunacy. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
July 16, 2007
Brian Orelli |
Business as Usual for Barr The maker of generic drugs gets sued twice in one week. Investors appear to be getting used to Barr's method of operation; the news of the lawsuits didn't hurt the stock price. |
BusinessWeek
January 26, 2004
Arelene Weintraub |
"Exploring New Paradigms in Sleep" Two top execs from Sanofi, maker of the popular drug Ambien, talk about the challenges of staying on top in the insomnia market. |
The Motley Fool
September 17, 2009
Brian Orelli |
Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it. |
The Motley Fool
March 9, 2004
David Nierengarten |
Sepracor's No Sleeper FDA approval for its sleeping medication sends Sepracor's stock up 70%. |
The Motley Fool
June 27, 2008
Brian Lawler |
Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal. |
AskMen.com
Jacob Franek |
How Much Sleep Do We Really Need? We ultimately attempt to answer, once and for all: How much sleep do we really need? First, however, it's important to understand how much sleep we're currently getting. |
The Motley Fool
July 24, 2006
Stephen D. Simpson |
Can Schering-Plough Continue to Shine? Cost-cutting and cholesterol drug sales continue apace, but is the company vulnerable? Investors, take note. |
